
Lundbeck's goal to become carbon neutral by 2050 heavily leans on the global Paris Agreement, but the pharmaceutical companies plans to reach this target before then, says Lundbeck CEO Deborah Dunsire in the wake of the company presenting its new climate plan.
"We will probably be moving our own internal operations toward carbon neutrality within the 2034 time frame, but the difficult part will be helping the supply chain, where the majority of our carbon footprint lies, to work with us to become carbon neutral," says Dunsire, who, however, is sympathetic towards the notion that the 2050 net-zero emissions goal lacks ambition.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app